Icon

BACTRIM DS (nda017377)- (800MG;160MG)

SULFAMETHOXAZOLE; TRIMETHOPRIM SUN PHARM INDUSTRIES
800MG;160MG
No No
Expired Expired
None None
None No
BACTRIM DS is indicated for: *Urinary Tract Infections - For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. *Acute Otitis Media - For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. *Acute Exacerbations of Chronic Bronchitis in Adults - For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of a single antimicrobial agent. *Shigellosis - For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. *Pneumocystis Carinii Pneumonia - For the treatment of documented Pneumocystis carinii pneumonia and for prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. *Travelers’ Diarrhea In Adults - For the treatment of traveler’s diarrhea due to susceptible strains of enterotoxigenic E. coli.
6 0 5
Total Other Developers 1
Drugs with Suitability No
800MG;160MG ** ** - - 4
NDA Sales Available Total Generic Sales Available
Yes 3
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** *** ***** ********** ******** ********, *** *********** **** ******** ******, ************, ************ (**) *****, ****** ****** (***) ***
****** *** ***** ********** ********* ********** **** ********** ****** **************** *********** ***** ***** *. **., ************, - *****, ******* (***) ***
****** ***** ****** ***** *************** ******* *********** ***** ********** ******, ************ *******,, ********, ********* ******, ***** (***) ***
****** ****** ****** ** ****** *************** ******* ******* *********** **** ** ** & **, ******* ******* ******** **** *******-***** *.*. **. **, ***.: ******, ***.: ******, *********, ** ******, ***** (***) ***
****** ****** ****** ** ****** *************** ******* ******* *********** ****** **.***, *** ** ***, **** ***** ********* *******-***** *******, ******* ******, *** *****, *********, ******* ******, ***** (***) ***
****** ********* ********* ********* *************** *******, ***. *********** ** ******* *****, *** ***** ******, *******, *** **** (**) *****, ****** ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-*, **. **. ***/*, ***/*, ***/*, **** **. *-*/*, ***** ***, ***** ********** ****, ********* (*******), ********* (******), ************ (********), ************, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.